Skip to main content

Table 1 Patients’ demographics and baseline disease characteristics

From: Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

 

TARGET (TNFi-INT/IR)

MOBILITY (MTX-IR)

MONARCH (MTX-INT/IR)

Low Hb (N = 186)

Normal Hb (N = 360)

Low Hb (N = 414)

Normal Hb (N = 783)

Low Hb (N = 92)

Normal Hb (N = 277)

Age, years

52.1 (13.9)

53.4 (11.5)

49.2 (12.6)

51.3 (11.0)

50.0 (13.3)

53.0 (11.9)

Female, n (%)

160 (86.0)

287 (79.7)

355 (85.8)

622 (79.4)

78.0 (84.8)

229 (82.7)

Male, n (%)

26 (14.0)

73 (20.3)

59 (14.3)

161 (20.6)

14 (15.2)

48 (17.3)

Weight, kg

74.7 (20.9)

80.0 (21.6)

69.5 (16.9)

76.9 (18.8)

69.3 (19.8)

73.0 (16.1)

BMI, kg/m2

28.7 (7.5)

30.0 (7.0)

26.7 (6.0)

29.1 (6.4)

26.2 (7.1)

27.5 (5.7)

Race, n (%)

 White

118 (63.4)

270 (75.0)

336 (81.2)

695 (88.8)

82 (89.1)

253 (91.3)

 Black

14 (7.5)

6 (1.7)

11 (2.7)

17 (2.2)

1 (1.1)

3 (1.1)

 Asian/Oriental

3 (1.6)

2 (0.6)

58 (14.0)

40 (5.1)

5 (5.4)

6 (2.2)

 Others

51 (27.4)

82 (22.8)

9 (2.2)

31 (4.0)

4 (4.4)

15 (5.4)

Duration of RA since diagnosis, years

12.2 (9.6)

12.0 (9.3)

8.6 (8.0)

9.3 (7.8)

6.3 (7.3)

7.7 (8.2)

Anti-CCP [n (%)] positive

147 (79.9)

275 (77.3)

350 (84.8)

686 (88.0)

73 (81.1)

199 (74.3)

Rheumatoid factor [n (%)] positive

147 (79.5)

262 (73.4)

344 (83.3)

665 (85.5)

63 (70.0)

172 (64.4)

TJC28 (0–28)

17.1 (7.4)

15.8 (6.6)

16.0 (6.7)

15.6 (6.6)

16.7 (6.4)

16.7 (6.2)

SJC28 (0–28)

14.5 (6.3)

13.1 (5.9)

12.2 (5.7)

11.8 (5.4)

13.3 (5.8)

12.8 (5.5)

HAQ-DI (0–3)

1.9 (0.6)

1.7 (0.6)

1.7 (0.7)

1.6 (0.6)

1.7 (0.5)

1.6 (0.6)

CRP, mg/L*

36.9 (30.5)

21.6 (21.4)

30.2 (28.5)

17.3 (18.5)

35.0 (35.0)

16.0 (21.5)

CDAI

46.0 (14.0)

42.4 (12.4)

41.2 (12.4)

40.1 (12.2)

43.6 (12.9)

42.8 (11.8)

DAS28-CRP

6.5 (1.0)

6.1 (0.9)

6.1 (0.9)

5.9 (0.9)

6.3 (0.9)

5.9 (0.9)

Pain-VAS, mm

75.9 (18.2)

70.7 (18.8)

66.2 (20.2)

64.7 (21.3)

71.5 (17.9)

71.5 (19.1)

Morning stiffness VAS, 0–100 mm

72.4 (22.0)

67.7 (23.1)

Not Available

Not Available

68.6 (20.5)

69.7 (20.2)

FACIT-Fatigue

22.8 (10.0)

23.8 (10.8)

25.3 (10.4)

27.0 (10.1)

23.0 (9.2)

24.0 (9.8)

  1. All values are mean (SD), unless specified otherwise
  2. N number of patients in each study group with low or normal Hb subgroup, BMI body mass index, CCP cyclic citrullinated peptide, CRP C-reactive protein, CDAI Clinical Disease Activity Index, DAS Disease Activity Scores, DAS28-CRP Disease Activity Score 28-joint count-C-reactive protein, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Stanford Health Assessment Questionnaire-Disability Index, Hb hemoglobin, MTX-INT/IR intolerant of, or an inadequate response to, MTX, MTX-IR An inadequate response to methotrexate, RA rheumatoid arthritis, SD standard deviation, SE standard error, SJC28 Swollen 28-Joint Count, TJC28 Tender 28-Joint Count, TNFi-INT/IR intolerant of, or an inadequate response to, tumor necrosis factor inhibitors, VAS visual analog scale
  3. *Significant difference in CRP between low and normal baseline Hb groups in MOBILITY study (P < 0.0001)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us